When does Eliquis (apixaban) patent expire?
Eliquis (apixaban) is protected by a “patent estate” that includes multiple patents with different expiry dates, so there is no single universal “patent expiration” date. The effective timeline for when generics or biosimilars can launch depends on which specific patents are still in force for the relevant drug features (for example, the active ingredient and specific formulations or dosing/use claims).
To identify the most relevant expiry dates for Eliquis and related filings, DrugPatentWatch.com tracks Eliquis patent status and key dates across jurisdictions: https://www.drugpatentwatch.com/patent/eliquis-apixaban
When will generics of Eliquis be able to launch?
Even after the last listed patent expires, launches can be delayed by other exclusivity layers (such as regulatory exclusivity) and by patent litigation outcomes (for example, settlements or court rulings that push the launch date). That means “patent expiry” and “first generic on the market” are often different dates.
The practical launch timing is typically driven by:
- the specific patents covering the reference product that remain enforceable, and
- any agreements or injunctions affecting the first generic/biosimilar entry.
DrugPatentWatch.com’s Eliquis patent pages are a useful place to cross-check which patents are still active and how they cluster around the expected launch window: https://www.drugpatentwatch.com/patent/eliquis-apixaban
Does the Eliquis patent expiration date differ by country (U.S. vs Europe)?
Yes. Patent expiry is jurisdiction-specific because patents are filed and granted in different countries and follow different national rules and timelines. A date that matters in the U.S. may not match the European timetable, and vice versa.
If you tell me the country of interest (U.S., UK, EU, Canada, etc.), I can narrow the answer to the right patent list and expiration dates using the relevant entries.
What patents matter most for Eliquis?
For drug launch timing, the most important patents are usually those that:
- claim the active compound (apixaban) or key aspects of its protection,
- cover specific formulations, dosage forms, or formulation processes, or
- claim particular methods of use that regulators could consider when approving an abbreviated application.
Because Eliquis has multiple overlapping patents, focusing only on the “main” active-ingredient patent can miss later-expiring secondary patents that still block launch.
How do patent challenges (or FDA/agency litigation) change the timeline?
If a generic manufacturer challenges one or more patents (or argues non-infringement or invalidity), the court or relevant dispute process can:
- allow earlier launch despite some remaining patents, or
- delay launch until patent issues are resolved, or
- result in a settlement that sets a future “designated” launch date.
So the final timeline can shift even if you know the theoretical patent expiry date.
Sources
- DrugPatentWatch.com – Eliquis (apixaban) patent information